Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

GlobeNewswireNov 25 09:32 ET

Immix Biopharma | 10-Q: Q3 2024 Earnings Report

SECNov 12 16:42 ET · Announcements

Immix Biopharma's Promising Therapeutic Candidate NXC-201 Fuels Buy Rating Amidst Strong Clinical and Financial Outlook

TipRanksOct 3 06:16 ET · Ratings

Express News | Immix Biopharma Inc: Now Dosing at Dose Expansion Level of 450 Mln Nxc-201 Car+T Cells

ReutersOct 2 09:33 ET

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

GlobeNewswireOct 2 09:32 ET

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

GlobeNewswireSep 19 09:31 ET